Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: observational study.
- Who it may be relevant to
- Registry conditions: Axial Spondylarthritis (axSpA), Psoriatic Arthritis (PsA). Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United Kingdom
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Clinical Characteristics, Treatment Patterns and Outcomes in Patients With axSpA and PsA Following Initiation of Bimekizumab, Risankizumab, Guselkumab, Upadacitinib or a TNF Inhibitor
Overview
This observational study will target patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who have started treatment with bimekizumab, upadacitinib, risankizumab, guselkumab, or a tumour necrosis factor-alpha inhibitor (e.g., adalimumab or etanercept) at NHS hospitals in the United Kingdom. Information from patients' medical records will be collected, and patients will complete surveys about their experiences with their treatment. The study will look at treatment effectiveness from both healthcare professionals' and patients' points of view.
Detailed description
Patient experience surveys will be administered prospectively throughout the study period, whereas the review of patients' medical records will be conducted retrospectively towards the end of the study period.
Interventions
- Other observational study
This is an observational study based on existing treatments prescribed prior to inclusion. No interventions are given as part of this research.
Primary outcome measures
- Number of participants that have achieved Low Disease Activity (LDA) at 12 months. [Time frame: At 12 months]
- Number of participants that have achieved Minimal Disease Activity (MDA) at 12 months. [Time frame: At 12 months]
- Change from baseline in PROM scores at 12 months. [Time frame: At 12 months]
Eligibility criteria
Inclusion criteria
- Participant has a clinical diagnosis of axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA).
- Participant has been prescribed advanced therapy within one month prior to enrolment in the study, to treat their axSpA or PsA.
- Participant is aged 18 years or older at enrolment.
Exclusion criteria
-Participation in a clinical trial at enrolment.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
United Kingdom · 1 center
- Royal National Hospital for Rheumatic Diseases — Bath
Identifiers
NCT: NCT07166315 · AG9827